echinacea purpurea: clinical use

Prescribing considerations

• Confirm the exact species, plant part and preparation because echinacea products are not interchangeable.
• The indication is supported by traditional use rather than product-specific clinical efficacy trials.
• Review immunosuppressive treatment and histories of atopy, immune disease or white-cell disorders.
• Escalate assessment if symptoms worsen or high fever develops.

Contraindications and cautions

• Hypersensitivity to echinacea, excipients or other Asteraceae family plants
• Allergic diathesis, including urticaria, atopic dermatitis or asthma
• Progressive systemic disorders such as tuberculosis or sarcoidosis
• Autoimmune disease
• Immunodeficiency or immunosuppression, including transplant history or cytostatic treatment
• Diseases of the white-cell system
• Children under 12 years
• Concomitant ciclosporin, methotrexate or other immunosuppressants

Monitoring

• No routine laboratory monitoring is specified for intended use.
• Monitor clinically for hypersensitivity, worsening infection symptoms or high fever.
• Report suspected reactions with precise product and ingredient details through the Yellow Card scheme.

Clinical pharmacology

A multi-constituent dry ethanolic root extract described as having immunostimulating activity. Its exact pharmacodynamic mechanism is unresolved, and relevant pharmacokinetic data are unavailable.

Formulation and product differences

• The selected products are beige, circular, convex, uncoated oral tablets containing dry Echinacea purpurea root extract.
• Products may use different species, plant parts, solvents and extraction methods, so evidence and safety information may not transfer between formulations.